RESUMEN
INTRODUCTION: Mental health symptoms such as depression, anxiety and sleep problems are commonly observed in individuals suffering from acute COVID-19 infection to post-COVID-19 syndrome. Studies have provided preliminary evidence for the efficacies of cognitive behavioural therapy, mindfulness-based interventions, acceptance and commitment therapy, and many other treatments for this population. Although there have been attempts to synthesise the literature on these psychological interventions, previous reviews have been limited in terms of the sources, symptoms and interventions that they included. Furthermore, most studies reviewed were conducted in early 2020, when COVID-19 had only recently been classified as a global pandemic. Since then, substantial research has been conducted. As such, we sought to provide an updated synthesis of the available evidence of treatments for the range of mental health symptoms associated with COVID-19. METHODS AND ANALYSIS: This scoping review protocol was developed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews. Systematic searches were carried out on scientific databases (PubMed, Web of Science, PsycINFO and Scopus) and clinical trial registries (ClinicalTrials.gov, WHO ICTRP, EU Clinical Trials Register and Cochrane Central Register of Controlled Trials) to identify studies that have or will assess the efficacy or any aspects of psychological treatment for acute to post-COVID-19 syndrome. The search was conducted on 14 October 2022 and identified 17 855 potentially eligible sources/studies published since 1 January 2020 (duplicates removed). Six investigators will independently carry out titles and abstract screening, full-text screening and data charting and the results will be summarised using descriptive statistics and narrative synthesis. ETHICS AND DISSEMINATION: Ethical approval is not required for this review. The results will be disseminated through a peer-reviewed journal, conference presentations and/or academic newspapers. This scoping review has been registered with Open Science Framework (https://osf.io/wvr5t).
Asunto(s)
Terapia de Aceptación y Compromiso , COVID-19 , Humanos , Salud Mental , Síndrome Post Agudo de COVID-19 , COVID-19/terapia , Ansiedad/terapia , Revisiones Sistemáticas como Asunto , Literatura de Revisión como AsuntoRESUMEN
Condition:
Post COVID-19 conditionLong COVID;D000086402;Long COVID
Primary outcome:
Tier 1 information: presence or absence of various symptoms of the study subjects (fever, cough, wet cough, blood sputum/hematoptysis, sore throat, wheezing, dyspnea/shortness of breath, chest pain, myalgia/arthralgia, convulsions, difficulty walking, enlarged lymph nodes, headache, altered consciousness/distraction, tiredness/fatigue, loss of appetite, abdominal pain, vomiting/nausea, diarrhea, abnormal sense of taste, abnormal sense of smell, conjunctivitis, and skin rash), basic information (demographic information, residence, marital status, presence of children, schooling/working status, class/working status, communication with family members and others), and basic information (demographic information, residence, marital status, presence of children, schooling/working status, class/working status, family and others). skin rash), basic information (demographic information, residential status, marital status, presence of children, schooling/work status, class/work status, communication with family/others), impact of new coronavirus sequelae, change in frequency of outings, worry, history of infection, diagnosis, history of testing, vaccination history, vaccination frequency, psychiatric treatment history.Tier 2 information: Cognitive function assessment (10 minutes): MoCA-J (Japanese version of Montreal Cognitive Assessment), Clinical global impression-severity assessment (2 minutes): CGI-S (Clinical Global Impression-severity) [Tier 2b information]: PHQ-9 (Patient Health Questionnaire-9), GAD-7 (Generalized Anxiety Disoeder-7), ISI (Insomnia Severity Index), and PDQ-D5 (Perceived Deficits Questionnaire-Depression 5), EuroQol-5D-5L (EQ 5D-5L), SWLS (Satisfaction with Life Scale) All questionnaires [Tier 2 a information], prescription details and drug history: prescription and drug history information [layer 2a information]
Tier 3 samples and information: Biological samples: blood (plasma, DNA) 20 mL Biological information: information obtained from analysis of biological samples, and brain neuroimaging (3D-T1, 3D-T2, rsfMRI, DTI, NM-MRI) and information obtained from their analysis - ePRO input information**: Layer 2a information, name, gender, birth date, name of medical institution, telephone number, e-mail address (name, telephone number and e-mail address are managed only within ePRO secretariat), etc.
Criteria:
Inclusion criteria: Patients (16 years of age or older, regardless of diagnosis or gender) who have received care at a medical institution approved to participate in this study as a collaborating institution due to COVID-19 infection, who have psychiatric symptoms after infection, and who have given written consent for enrollment in this registry. Minors and persons lacking the capacity to consent will be included in this study. If minors or persons lacking the capacity to consent wish to participate in the study, consent shall be obtained from the person himself/herself as well as from a substitute consenting party. In the first year of the study, minors under 16 years of age will not be included, and for minors under 18 years of age, consent will be obtained from the individual and a surrogate.As for the non-infected control group, healthy subjects obtained in the previous research project "Elucidation of Diversity and Age-related Changes in Neural Circuitry in the Human Brain" at Nagoya University will be included.
Exclusion criteria: Those who are unable to obtain the consent of the patient or those whose participation in this study is deemed inappropriate by the attending physician, such as those whose medical condition is expected to worsen as a result of participating in this study.